These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27052896)

  • 1. Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer.
    Kulhari H; Pooja D; Shrivastava S; Kuncha M; Naidu VGM; Bansal V; Sistla R; Adams DJ
    Sci Rep; 2016 Apr; 6():23179. PubMed ID: 27052896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy.
    Aleanizy FS; Alqahtani FY; Seto S; Al Khalil N; Aleshaiwi L; Alghamdi M; Alquadeib B; Alkahtani H; Aldarwesh A; Alqahtani QH; Abdelhady HG; Alsarra I
    Int J Nanomedicine; 2020; 15():5433-5443. PubMed ID: 32801698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
    Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B
    Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.
    Chan C; Cai Z; Reilly RM
    Pharm Res; 2013 Aug; 30(8):1999-2009. PubMed ID: 23615858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab.
    Ma P; Zhang X; Ni L; Li J; Zhang F; Wang Z; Lian S; Sun K
    Int J Nanomedicine; 2015; 10():2173-90. PubMed ID: 25834432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cellular and transcriptional targeting of breast cancer stem cells via anti-HER2 nanobody conjugated PAMAM dendrimers.
    Reshadmanesh A; Rahbarizadeh F; Ahmadvand D; Jafari Iri Sofla F
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S105-S115. PubMed ID: 30246563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells.
    Varshosaz J; Davoudi MA; Rasoul-Amini S
    J Liposome Res; 2018 Dec; 28(4):285-295. PubMed ID: 28826287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells.
    Miyano T; Wijagkanalan W; Kawakami S; Yamashita F; Hashida M
    Mol Pharm; 2010 Aug; 7(4):1318-27. PubMed ID: 20527783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PE38-based gene therapy of HER2-positive breast cancer stem cells via VHH-redirected polyamidoamine dendrimers.
    Moradian C; Rahbarizadeh F
    Sci Rep; 2021 Jul; 11(1):15517. PubMed ID: 34330942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
    Rodallec A; Brunel JM; Giacometti S; Maccario H; Correard F; Mas E; Orneto C; Savina A; Bouquet F; Lacarelle B; Ciccolini J; Fanciullino R
    Int J Nanomedicine; 2018; 13():3451-3465. PubMed ID: 29950829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer.
    Lemos LG; Victorino VJ; Herrera AC; Aranome AM; Cecchini AL; Simão AN; Panis C; Cecchini R
    Int Immunopharmacol; 2015 Jul; 27(1):8-14. PubMed ID: 25937481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
    Rodallec A; Sicard G; Giacometti S; Carré M; Pourroy B; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
    Int J Nanomedicine; 2018; 13():6677-6688. PubMed ID: 30425482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
    Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
    J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.